Abcam, ab263182, Human EIF1 knockout HCT116 cell lysate

Size: 1Kit
EIF1 KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 16 bp deletion in exon1 and Insertion of the selection cassette in exon1.
Key facts
Cell type:HCT116,
Species or organism:Human,
Tissue:Colon,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 16 bp deletion in exon1 and Insertion of the selection cassette in exon1.,
Disease:Carcinoma

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-EIF1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
EIF1 also known as 'eukaryotic translation initiation factor 1' plays a vital role in the initiation of protein synthesis. Its molecular mass is approximately 12 kDa. eIF1 functions mechanically by binding to the 40S ribosomal subunit which is essential for recruiting the initiation codon and maintaining the fidelity of start site selection during translation. Expression of eIF1 occurs in various tissues particularly higher in proliferative cells due to its role in protein synthesis.
Biological function summary
Eukaryotic translation initiation factor 1 facilitates the formation of the translation pre-initiation complex. It is an integral component of the eIF1A- and eIF2-associated assembly that is important for the proper translation initiation. This factor acts to stabilize the pre-initiation complex by preventing premature joining with the 60S ribosomal subunit ensuring accurate translation initiation sites are selected across a range of mRNAs.
Pathways
EIF1 is primarily involved in the mRNA translation initiation pathway. This pathway is important for regulating protein synthesis and gene expression. eIF1 interacts closely with other initiation factors like eIF2 which carries the initiator methionyl-tRNA and eIF3 which binds to the 40S ribosomal subunit to form the functional ribosome assembly. Additionally eIF1’s role in translation initiation is also linked to cellular stress responses influencing how cells adapt to changing environmental conditions.
Aberrant expression or malfunction of eIF1 may contribute to cancer and neurological disorders. Overexpression of eIF1 has been observed in some types of cancer suggesting a connection with tumorigenesis due to uncontrolled protein synthesis. Additionally eIF1’s interaction with other transcription factors could influence neurodegenerative diseases where disruptions in protein homeostasis are an important feature. Understanding eIF1's role could therefore aid in developing novel therapeutic strategies for these conditions.